drugset / Trial / NCT05942378
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label study evaluating the efficacy and safety of HRXG-K-1939 in combination with Adebrelimab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) in patients with advanced solid tumors. HRXG-K-1939 will be administered to patients in a dose escalation regimen to determine a recommended dose for expansion.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2025-09-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRXG-K-1939 | Messenger RNA (mRNA) | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |